Servi­er plans to pay $2.5 bil­lion to ac­quire Day One Bio­phar­ma­ceu­ti­cals in a deal that will give it ac­cess to rare on­col­o­gy med­i­cines, in­clud­ing the mar­ket­ed brain tu­mor treat­ment Ojem­da.

The French phar­ma said on Fri­day it will pay $21.50 a share DAWN in cash, mark­ing a 68% pre­mi­um over Day One's Thurs­day clos­ing price. The Cal­i­for­nia biotech went pub­lic in May 2021 at $16 a pop. The deal is slat­ed to close in the sec­ond quar­ter and adds to a string of as­sets that Servi­er has brought in over the past six months.

The deal marks at least the 10th bio­phar­ma ac­qui­si­tion so far this year, ac­cord­ing to an End­points News track­er. Eli Lil­ly, GSK and Gilead have each forged multi­bil­lion-dol­lar deals this year as they look to ex­pand their pipeline prowess for years to come.

Pfiz­er was a late ar­rival to the obe­si­ty gold rush, but it just hit its first seam.

The GLP-1 shot, li­censed from Hangzhou-based drug­mak­er Sci­wind Bio­sciences just a lit­tle over a week ago, was ap­proved in Chi­na for weight man­age­ment, Sci­wind said Fri­day, mak­ing it Pfiz­er’s first ap­proved obe­si­ty med­i­cine.

In an atyp­i­cal arrange­ment be­tween US and Chi­nese com­pa­nies, Pfiz­er did not take ex-Chi­na rights to Sci­wind’s drug. In­stead, it took ex­clu­sive sales rights for the prod­uct in main­land Chi­na it­self, agree­ing to pay a to­tal of $495 mil­lion. Sci­wind is still re­spon­si­ble for any fur­ther de­vel­op­ment of the shot, as well as reg­is­tra­tion, man­u­fac­tur­ing and sup­ply.

💵 Sol­id Bio­sciences an­nounces $240M pri­vate place­ment: The funds are ear­marked for pipeline de­vel­op­ment, busi­ness de­vel­op­ment and “oth­er gen­er­al cor­po­rate pur­pos­es,” Sol­id said Fri­day. Its lead can­di­date, a gene ther­a­py for Duchenne mus­cu­lar dy­s­tro­phy, is in an on­go­ing Phase 1/2 tri­al. Sol­id said last month it would dose the first pa­tient in a Phase 3 this quar­ter.

🔍 Roche de­tails lu­pus da­ta: The com­pa­ny is shar­ing more in­for­ma­tion months af­ter an­nounc­ing that its CD20-tar­get­ing an­ti­body Gazy­va suc­ceed­ed in a Phase 3 tri­al for sys­temic lu­pus ery­the­mato­sus. At one year, more than three-quar­ters (76.7%) of par­tic­i­pants who re­ceived Gazy­va plus stan­dard ther­a­py achieved at least a four-point im­prove­ment on an in­dex com­mon­ly used to mea­sure pa­tients’ progress, com­pared to 53.5% of peo­ple who got a place­bo plus stan­dard ther­a­py. Roche said the da­ta are “be­ing dis­cussed” with the FDA and EMA.